<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Epithelial-to-mesenchymal transition (EMT) plays a pivotal role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion and dissemination </plain></SENT>
<SENT sid="1" pm="."><plain>EMT occurs predominantly at the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> edge where it is induced by cytokines, the extracellular matrix environment, or <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell, it is further mediated by several transcription factors and microRNAs </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to explore the expression of EMT-associated genes at the invasive front in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and to evaluate their prognostic significance </plain></SENT>
<SENT sid="4" pm="."><plain>EXPERIMENTAL DESIGN: We evaluated the expression of 13 EMT-associated genes at the invasion front of 30 colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> by quantitative real-time PCR </plain></SENT>
<SENT sid="5" pm="."><plain>Immunostaining against zinc finger E-box-binding homeobox 2 (ZEB2) was carried out on 175 primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> specimens and 30 colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> and correlated to clinical and histopathologic data </plain></SENT>
<SENT sid="6" pm="."><plain>DLD-1 cells were transfected with siRNA and subjected to migration and invasion assays </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Gene expression analysis and immunohistochemistry showed an upregulation of ZEB2 at the invasion front in primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Overexpression of ZEB2 at the invasion front correlated significantly with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage in primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, univariate and multivariate analysis revealed overexpression of ZEB2 at the invasion front as an independent prognostic marker for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival </plain></SENT>
<SENT sid="10" pm="."><plain>Downregulation of ZEB2 by siRNA decreased the migration and invasion capacity of DLD-1 cells in vitro </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Overexpression of ZEB2 at the invasion front correlates with <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and predicts <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival in primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Therefore, ZEB2 may be interesting as biomarker and potential target for treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>